All News

The phase 3 trial showed a statistically significant improvement in overall survival (OS) and composite complete remission rate.

The growth of the pipeline has led to increases in insurance carriers’ specialty plan spend.

A study of the second HIV patient to undergo successful stem cell transplantation from donors with an HIV-resistant gene found that there was no active viral infection in the patient’s blood 30 months after they stopped antiretroviral therapy.

Tim Ulbrich, PharmD, co-founder and CEO of Your Financial Pharmacist, explains how your finances may be affected by the coronavirus and how your can reinforce your financial situation.

The US Pharmacopeia (USP) is providing free technical assistance to developers of antiviral drugs and vaccines that will support the public health response to the coronavirus disease 2019 (COVID-19) pandemic.

Pharmacy Moms Group special task force develops guidelines as precautions are implemented amid the COVID-19 pandemic.

A new commentary suggests that public health leaders should guide world leaders through the coronavirus disease 2019 pandemic.

Only 15% of those at risk are currently using PrEP.

A report published noted that there are subpopulations of pediatric patients with COVID-19 who have an increased risk for more significant illness.

Steven C. Hoffart, PharmD, owner and operator of Magnolia Pharmacy in Magnolia, Texas, said his pharmacy had run out of prepared hand sanitizer when he saw a need for many people in his area.

The 12 groups represent practice settings of nearly all pharmacists in the United States.

“We’re pretty devastated,” said Jessica Harris, a friend of Rutter, in an interview with WFSB. “She beat cancer and lost the battle to coronavirus—it’s just crazy.”

More than 90% of physicians, nurses, and pharmacists are concerned about COVID-19 affecting their patients, whereas 68% of doctors and 67% of nurses feel they are reasonably prepared for a COVID-19 outbreak in their area.

Four out of 8 manufacturers of hydroxychloroquine, an anti-malarial drug that had shown some success treating the symptoms of the novel coronavirus (COVID-19), are already experiencing shortages.

A new report from the CDC has found that a significant portion of hospitalizations in the United States have come from younger adults.

The study focused on whether moderate alcohol intake is related to reductions in amyloid-beta deposition or is protective via amyloid-independent mechanisms in the living human brain since little information was available.

The FDA has released a statement addressing the issue, stating that the organization is “not aware of scientific evidence connecting the use of NSAIDs, like ibuprofen, with worsening COVID-19 symptoms.”

CVS mistakenly sent unproven information to employees surrounding drinking warm water to combat the novel coronavirus.

All 3 trials reached their primary endpoints, specifically percentage change in low-density lipoprotein cholesterol (LDL-C) from baseline to 17 months and time-adjusted percentage change in LDL-C from baseline from 3 to 18 months.

The findings highlight the critical role played by excess visceral adiposity in the progression of fibrosis among HIV-infected patients with nonalcoholic fatty liver disease, according to the study authors.

As the COVID-19 pandemic continues, a key issue for pharmacists, other health care professionals, and patients is the potential for disruptions in the US medication supply chain.

Top news of the week from Pharmacy Times surrounding the novel coronavirus.

The drug was previously approved to treat HCV in adults

The General Pharmaceutical Council has made plans to temporarily re-register pharmacists and pharmacy technicians should the government launch a state of emergency due to the novel coronavirus.

Researchers in Australia tested blood samples at 4 different time points in an otherwise healthy adult woman who presented with COVID-19 and had mild-to-moderate symptoms requiring hospital admission.

This will be the first global study of tocilizumab in this setting and is expected to begin enrolling in early April, with a target of approximately 330 patients globally.

Chloroquine and remdesivir are not FDA-approved for a COVID-19 indications.

Although preventive measures may be largely the same for patients with cancer during the COVID-19, the pandemic could result in difficult treatment decisions.